✕

Expertise

Services

Solutions

About Us

Resources

Request Quote

    Contact Us
    • Home
    • Blood–Brain Barrier Risk Check: MDCK-MDR1 P-gp Substrate Assessment for CNS Drug Candidates

    Blood–Brain Barrier Risk Check: MDCK-MDR1 P-gp Substrate Assessment for CNS Drug Candidates

    Challenge

    A client developing a CNS-targeted small molecule needed to determine whether their lead compound was a substrate of P-glycoprotein (P-gp, MDR1/ABCB1)—a key efflux transporter at the blood–brain barrier that can limit brain exposure. Early bidirectional permeability results (A→B vs B→A) suggested active efflux, but for IND-enabling documentation the client needed clear, mechanistic confirmation using established P-gp inhibitor controls.

    The key challenge was building an inhibitor strategy that was:

    • Mechanistically clean (highly selective for P-gp to support definitive interpretation), and
    • Regulatory-relevant (commonly accepted inhibitors aligned with FDA/EMA DDI and transporter expectations).

    Solution

    NEBIOLAB implemented a focused MDCK-MDR1 (MDCK II–MDR1) assay workflow designed for confident, submission-ready decision making.

    1) Assay Design and Setup

    • MDR1-transfected MDCK II cells were cultured on Transwell inserts, with wild-type MDCK run in parallel to separate transporter-mediated effects from baseline permeability.
    • The compound was tested in both directions:
      • Apical → Basolateral (A→B) and
      • Basolateral → Apical (B→A)
    • We calculated the efflux ratio (ER = Papp B→A / Papp A→B) as the primary indicator of active transport.

    2) P-gp Inhibitor Strategy (Gold-Standard + Clinically Relevant)

    To eliminate ambiguity and strengthen regulatory confidence, we used two complementary inhibitors in parallel:

    • Elacridar (GF120918): a gold-standard, potent inhibitor widely used for mechanistic confirmation of P-gp–mediated efflux.
    • Cyclosporin A: a clinically relevant inhibitor frequently referenced in transporter/DDI contexts, providing translational support for regulatory packages.

    Using both inhibitors improves interpretability: one optimizes selectivity and potency, the other adds clinical relevance.

    3) Assay Controls and Monolayer Integrity

    To ensure data quality and rule out confounders:

    • Digoxin was included as a probe P-gp substrate control.
    • TEER measurements and Lucifer Yellow leakage testing were performed to confirm tight junction integrity and exclude compromised monolayers that can falsely inflate permeability.

    Outcome

    • Without inhibitor, the compound showed an efflux ratio (ER) of 4.7, consistent with active P-gp transport.
    • With Elacridar, ER decreased to 1.2, providing strong mechanistic evidence for P-gp–mediated efflux.
    • With Cyclosporin A, ER decreased to 1.6, offering clinically relevant corroboration.
    • This dual-inhibitor confirmation provided both mechanistic clarity and regulatory confidence, enabling the client to move forward with an IND submission supported by transporter-definitive data.

    Why it matters

    For CNS drug discovery, confirming P-gp substrate liability early can prevent downstream surprises, guide structure–property ptimization, and inform brain penetration risk. By pairing Elacridar (mechanistic gold standard) with Cyclosporin A (clinical relevance), NEBIOLAB delivered a regulatory-ready MDCK-MDR1 transporter package that minimizes review questions and supports faster development decisions.

    Speak To Our Scientist About Your Multiplex Cytokine Assay, Cytokine Quantification On Meso Scale Discovery

    SPEAK TO OUR SCIENTISTS

    Similar Case Study Articles

    Explore Our Expertise